Canada - English - Health Canada

teva canada limited - naloxone (naloxone hydrochloride dihydrate); buprenorphine (buprenorphine hydrochloride) - tablet - 0.5mg; 2mg - naloxone (naloxone hydrochloride dihydrate) 0.5mg; buprenorphine (buprenorphine hydrochloride) 2mg - opiate partial agonists

Canada - English - Health Canada

mylan pharmaceuticals ulc - buprenorphine (buprenorphine hydrochloride); naloxone (naloxone hydrochloride dihydrate) - tablet - 2mg; 0.5mg - buprenorphine (buprenorphine hydrochloride) 2mg; naloxone (naloxone hydrochloride dihydrate) 0.5mg - opiate partial agonists

Canada - English - Health Canada

mylan pharmaceuticals ulc - buprenorphine (buprenorphine hydrochloride); naloxone (naloxone hydrochloride dihydrate) - tablet - 8mg; 2mg - buprenorphine (buprenorphine hydrochloride) 8mg; naloxone (naloxone hydrochloride dihydrate) 2mg - opiate partial agonists

Canada - English - Health Canada

pharmascience inc - buprenorphine (buprenorphine hydrochloride); naloxone (naloxone hydrochloride dihydrate) - tablet - 2mg; 0.5mg - buprenorphine (buprenorphine hydrochloride) 2mg; naloxone (naloxone hydrochloride dihydrate) 0.5mg - opiate partial agonists

Canada - English - Health Canada

pharmascience inc - buprenorphine (buprenorphine hydrochloride); naloxone (naloxone hydrochloride dihydrate) - tablet - 8mg; 2mg - buprenorphine (buprenorphine hydrochloride) 8mg; naloxone (naloxone hydrochloride dihydrate) 2mg - opiate partial agonists

Canada - English - Health Canada

teva canada limited - buprenorphine (buprenorphine hydrochloride); naloxone (naloxone hydrochloride dihydrate) - tablet - 8mg; 2mg - buprenorphine (buprenorphine hydrochloride) 8mg; naloxone (naloxone hydrochloride dihydrate) 2mg - opiate partial agonists

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - buprenorphine hydrochloride 2.16mg (equiv 2 mg buprenorphine);  ; naloxone hydrochloride dihydrate 0.61mg (equiv 0.5 mg naloxone);   - sublingual tablet - active: buprenorphine hydrochloride 2.16mg (equiv 2 mg buprenorphine)   naloxone hydrochloride dihydrate 0.61mg (equiv 0.5 mg naloxone)   excipient: acesulfame potassium citric acid monohydrate lactose monohydrate lemon flavour sd01600158 lime flavour sd01620018 magnesium stearate maize starch mannitol povidone sodium citrate - treatment of opiate dependence, within a framework of medical, social and psychological treatment. naloxone is included to deter intravenous misuse of the product.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - buprenorphine hydrochloride 8.64mg (equiv 8 mg buprenorphine);  ;  ; naloxone hydrochloride dihydrate 2.44mg (equiv 2 mg naloxone);   - sublingual tablet - active: buprenorphine hydrochloride 8.64mg (equiv 8 mg buprenorphine)     naloxone hydrochloride dihydrate 2.44mg (equiv 2 mg naloxone)   excipient: acesulfame potassium citric acid monohydrate lactose monohydrate lemon flavour sd01600158 lime flavour sd01620018 magnesium stearate maize starch mannitol povidone sodium citrate - treatment of opiate dependence, within a framework of medical, social and psychological treatment. naloxone is included to deter intravenous misuse of the product.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 5 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 20 mg - drug delivery system, transdermal - excipient ingredients: povidone; oleyl oleate; polyethylene; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.